Klivira
Request demo

Streamlining Medicaid Aimovig Prior Authorization Workflows

Navigating Medicaid Aimovig prior authorization requires a precise understanding of state-specific guidelines and managed care organization (MCO) protocols. Klivira streamlines these complex workflows, improving efficiency for this critical preventive migraine therapy.

For revenue cycle directors and prior authorization coordinators, securing timely approvals for specialty medications like Aimovig (erenumab) under Medicaid presents unique challenges. The fragmented nature of Medicaid administration, split between Fee-for-Service (FFS) and Managed Care models, demands adaptable strategies to minimize denials and accelerate patient access.

Aimovig (Erenumab) in the Medicaid Context

Aimovig, or erenumab, is a CGRP receptor antagonist indicated for the preventive treatment of both chronic and episodic migraine. As a specialty pharmaceutical, it typically falls under strict prior authorization requirements across most payer types, including Medicaid. Given its cost and specific indications, Medicaid programs often implement step therapy protocols, requiring trials of generic preventive therapies before approving CGRP antagonists.

Understanding Medicaid Prior Authorization for Specialty Drugs

Medicaid's prior authorization landscape for specialty drugs like Aimovig is highly variable. Each state's Medicaid program establishes its own medical necessity criteria, which MCOs operating within that state must adhere to as a baseline. The process can differ significantly based on whether the member is enrolled in a Fee-for-Service (FFS) plan, where PA routes to the state agency's fiscal agent, or a Medicaid Managed Care plan, which directs PA to the specific MCO.

Key Prior Authorization Channels and Requirements

Submitting prior authorizations for Aimovig under Medicaid involves diverse channels. FFS submissions typically use the state Medicaid portal, while managed care plans require submission through individual MCO provider portals. The X12 278 transaction is also supported by some state Medicaid agencies and MCOs for electronic prior authorization (ePA). Compliance with state-specific medical necessity criteria, often found in state Medicaid policy libraries, is paramount for approval.

Impact of CMS-0057-F on Medicaid Managed Care

Medicaid Managed Care Organizations (MCOs) are directly impacted by CMS-0057-F, which mandates specific PA decision timeframes—72 hours for standard requests and 24 hours for expedited—and requires the implementation of FHIR-based Prior Authorization APIs on a phased timeline. While traditional FFS Medicaid is less directly impacted by the API requirements, the rule underscores a broader push for interoperability across all government-funded healthcare programs.

Klivira's Approach to Medicaid Aimovig PA

Klivira's platform is engineered to navigate the complexities of Medicaid Aimovig prior authorization. We identify the correct delivery model—FFS or managed care—and route requests to the appropriate state agency or MCO. Our system incorporates state Medicaid agency rules as the foundational criteria, ensuring MCOs do not impose more restrictive requirements. This approach streamlines the submission process, reducing administrative burden and accelerating access to essential treatments.

Frequently asked questions

What are common reasons for Aimovig PA denials under Medicaid?

Denials for Aimovig (erenumab) under Medicaid often stem from insufficient documentation of prior generic preventive therapy trials, failure to meet specific diagnostic criteria for chronic or episodic migraine, or incomplete submission of required clinical data. Adherence to the state's medical necessity criteria, as outlined in their policy library, is crucial.

How do state Medicaid agencies and MCOs differ in their Aimovig PA processes?

State Medicaid agencies directly manage prior authorizations for Fee-for-Service (FFS) members, typically through their state portals. Managed Care Organizations (MCOs) handle PA for their enrolled members, using their own provider portals and internal processes. While MCOs must follow state Medicaid medical necessity criteria, their specific submission workflows and documentation requirements can vary.

Is step therapy required for Aimovig approval by Medicaid?

Yes, step therapy is a common requirement for specialty drugs like Aimovig (erenumab) across many Medicaid programs. Providers are often required to document trials of less costly, generic preventive migraine therapies before Aimovig will be approved. Specific step therapy protocols vary by state and MCO.

How does CMS-0057-F affect Medicaid prior authorization for Aimovig?

CMS-0057-F directly impacts Medicaid Managed Care Organizations (MCOs), mandating faster PA decision timeframes (72 hours standard, 24 hours expedited) and requiring the adoption of FHIR-based Prior Authorization APIs. This aims to improve the efficiency and transparency of the PA process for drugs like Aimovig for Medicaid managed care members.

Can Klivira integrate with both state Medicaid portals and MCO portals for Aimovig PA?

Yes, Klivira's platform is designed to connect with diverse payer channels. This includes routing prior authorization requests to state Medicaid portals for Fee-for-Service submissions and integrating with various MCO provider portals for managed care plans, leveraging X12 278 where supported to ensure comprehensive coverage for Aimovig PA.

Related coverage

Other aimovig prior authorization by payer

Other aimovig prior authorization by specialty

Ready to automate prior auth for this drug?

See how Klivira automates prior authorizations for your team.

Request a demo